Neumora Therapeutics reported disappointing results for its experimental depression treatment navacaprant, with shares plummeting 80%. The company’s Phase 3 trial failed to show a statistically significant improvement in key endpoints. CEO Henry Gosebruch noted the firm’s strong financial foundation and plans to provide updates on the treatment program at an upcoming conference.
Source: https://www.investopedia.com/neumora-therapeutics-stock-tanks-as-its-depression-drug-misses-goals-8768109